Bold claim: a common water pill, already FDA-approved for heart and blood pressure issues, might speed up HIV medicines and dampen inflammation. That’s the takeaway from new work by the Valente lab at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology.
In a study using HIV-infected mice engineered with human immune cells, researchers combined standard first-line antiretroviral therapy with a long-acting form of spironolactone, the widely used diuretic. The results, published in Emerging Microbes & Infections, showed that adding spironolactone reduced cell-associated HIV RNA in the body by more than fourfold and broadly lowered inflammatory activity. Importantly, the amount of proviral DNA—HIV’s genetic material that can persist in the body—did not change, indicating that spironolactone appears to dampen viral activity rather than eliminate infected cells.
If this early data holds in further studies, spironolactone could become a valuable adjunct to HIV treatment by enhancing drug effectiveness and reducing inflammation, without altering the reservoir of infected cells. You can read the full news story linked in the original report for more details: https://wertheim.scripps.ufl.edu/2025/12/01/common-water-pill-spironolactone-may-help-hiv-medicines-work-faster-and-reduce-inflammation-early-study-suggests/.
